Bioatla Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters

Nov 06, 2024

* Bioatla Inc is expected to show no change in quarterly revenue when it reports results on November 7 for the period ending September 30 2024

*

* LSEG's mean analyst estimate for Bioatla Inc is for a loss of 36 cents per share.

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months.

* Wall Street's median 12-month price target for Bioatla Inc is $10.00, above its last closing price of $2.07.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.47 -0.44 -0.44 Met -0.5

Mar. 31 2024 -0.54 -0.54 -0.48 Beat 11.4

Jan. 1 0001 -0.88 -0.79 -0.56 Beat 29.3

Sep. 30 2023 -0.82 -0.80 -0.70 Beat 12.5

Jun. -0.63 -0.64 -0.75 Missed -17.2

30 2023

Mar. 31 2023 -0.63 -0.63 -0.58 Beat 7.6

Jan. 1 0001 -0.62 -0.70 -0.63 Beat 9.7

Sep. 30 2022 -0.80 -0.80 -0.69 Beat 13.8

This summary was machine generated November 6 at 05:04 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2481129946"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481129946\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2481129946?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 13:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481129946","market":"us","top_or_hot":-1,"title":"Bioatla Inc    expected to post a loss of 36 cents a share - Earnings Preview","media":"Reuters","content":"<html><body><p>* Bioatla Inc     is expected to show no change in quarterly revenue when it reports  results on November 7 for the period ending September 30 2024</p><p>   * </p><p>   * LSEG's mean analyst estimate for Bioatla Inc is for a loss of 36 cents per share. </p><p>   * The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * Wall Street's median 12-month price target for Bioatla Inc is $10.00, above its last closing price of $2.07. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %</p><p>              E®                               MISSED  </p><p>Jun. 30 2024  -0.47       -0.44      -0.44     Met     -0.5</p><p>Mar. 31 2024  -0.54       -0.54      -0.48     Beat    11.4</p><p>Jan. 1 0001   -0.88       -0.79      -0.56     Beat    29.3</p><p>Sep. 30 2023  -0.82       -0.80      -0.70     Beat    12.5</p><p>Jun.        -0.63       -0.64      -0.75     Missed  -17.2</p><p>30 2023                                                </p><p>Mar. 31 2023  -0.63       -0.63      -0.58     Beat    7.6</p><p>Jan. 1 0001   -0.62       -0.70      -0.63     Beat    9.7</p><p>Sep. 30 2022  -0.80       -0.80      -0.69     Beat    13.8</p><p>This summary was machine generated November 6 at 05:04 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bioatla Inc    expected to post a loss of 36 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioatla Inc    expected to post a loss of 36 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-11-06 13:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>* Bioatla Inc     is expected to show no change in quarterly revenue when it reports  results on November 7 for the period ending September 30 2024</p><p>   * </p><p>   * LSEG's mean analyst estimate for Bioatla Inc is for a loss of 36 cents per share. </p><p>   * The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * Wall Street's median 12-month price target for Bioatla Inc is $10.00, above its last closing price of $2.07. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %</p><p>              E®                               MISSED  </p><p>Jun. 30 2024  -0.47       -0.44      -0.44     Met     -0.5</p><p>Mar. 31 2024  -0.54       -0.54      -0.48     Beat    11.4</p><p>Jan. 1 0001   -0.88       -0.79      -0.56     Beat    29.3</p><p>Sep. 30 2023  -0.82       -0.80      -0.70     Beat    12.5</p><p>Jun.        -0.63       -0.64      -0.75     Missed  -17.2</p><p>30 2023                                                </p><p>Mar. 31 2023  -0.63       -0.63      -0.58     Beat    7.6</p><p>Jan. 1 0001   -0.62       -0.70      -0.63     Beat    9.7</p><p>Sep. 30 2022  -0.80       -0.80      -0.69     Beat    13.8</p><p>This summary was machine generated November 6 at 05:04 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCAB","symbol_name":"BioAtla, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2481129946","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481129946","pubTimestamp":1730869497,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Bioatla Inc     is expected to show no change in quarterly revenue when it reports  results on November 7 for the period ending September 30 2024   *    * LSEG's mean analyst estimate for Bioatla In","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BCAB":"BioAtla, Inc."},"translate_title":"Bioatla Inc预计每股亏损36美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCAB":1},"content_text":"* Bioatla Inc     is expected to show no change in quarterly revenue when it reports  results on November 7 for the period ending September 30 2024   *    * LSEG's mean analyst estimate for Bioatla Inc is for a loss of 36 cents per share.    * The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"     * The mean earnings estimate of analysts was unchanged in the last three months.    * Wall Street's median 12-month price target for Bioatla Inc is $10.00, above its last closing price of $2.07. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRIENDING        ARTESTIMAT  ESTIMATE             MET,    SE %              E®                               MISSED  Jun. 30 2024  -0.47       -0.44      -0.44     Met     -0.5Mar. 31 2024  -0.54       -0.54      -0.48     Beat    11.4Jan. 1 0001   -0.88       -0.79      -0.56     Beat    29.3Sep. 30 2023  -0.82       -0.80      -0.70     Beat    12.5Jun.        -0.63       -0.64      -0.75     Missed  -17.230 2023                                                Mar. 31 2023  -0.63       -0.63      -0.58     Beat    7.6Jan. 1 0001   -0.62       -0.70      -0.63     Beat    9.7Sep. 30 2022  -0.80       -0.80      -0.69     Beat    13.8This summary was machine generated November 6 at 05:04 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}